A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Purpose
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Condition
- Lymphoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participant must be 18 years or older at the time of signing the informed consent form (ICF). - Histologically confirmed primary central nervous system (CNS) lymphoma (PCNSL) prior to screening, as assessed by local pathology. - Transplant-ineligible based on physician's assessment and meeting at least one of the following criteria: age ≥65 years or HCT-CI (Hematopoietic Cell Transplantation-specific Comorbidity Index) score ≥3. - Participant must be suitable, per investigator, to receive a high dose methotrexate (HD-MTX) based treatment regimen. - Prior to signing ICF, anti-cancer therapy for the treatment of PCNSL must only include standard of care regimens, with or without corticosteroids given for disease-related symptoms. - Prior to ICF signature, participant's disease must be sensitive to prior high-dose methotrexate-based regimens, as demonstrated by a complete response (CR, no remaining signs of PCNSL) or a partial response (PR, signs of PNCSL mostly gone) per Investigator's assessment, based on the International Primary CNS Lymphoma Collaborative Group (IPCG) criteria. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. - Individuals of childbearing potential (IOCBP) must have a negative highly sensitive pregnancy test within 24 hours prior to the start of study intervention.
Exclusion Criteria
- Participant has a diagnosis of secondary CNS lymphoma due to systemic disease. - Primary intraocular lymphoma (PIOL)/ Primary vitreoretinal lymphoma (PVRL) and isolated cerebrospinal fluid (CSF) disease. - Any significant medical condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she was to participate in the study based on investigator's judgement. - History of another primary malignancy that has not been in remission for ≥2 years. - Prior treatment with CAR T-cell or any other gene therapy product that utilizes human genome-editing technology. - History of or active human immunodeficiency virus (HIV). - Active hepatitis B or active hepatitis C. - Active autoimmune disease requiring immunosuppressive therapy. - Other protocol-defined Inclusion/Exclusion criteria apply.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Liso-cel Administration |
|
Recruiting Locations
Washington University in St. Louis and nearby locations
Washington University School of Medicine in St. Louis
St Louis, Missouri 63110-1010
St Louis, Missouri 63110-1010
Contact:
Armin Ghobadi, Site 0316
314-454-8323
Armin Ghobadi, Site 0316
314-454-8323
More Details
- NCT ID
- NCT07015242
- Status
- Recruiting
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study Contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
Clinical.Trials@bms.com